---
run_id: halo-evidence-vs-diagnosis-validation-v9-substrate-workflow-03
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
model_condition: substrate_workflow
run_number: 3
model_name: gemma-4-31b-it-mlx
model_id: gemma-4-31b-it-mlx
model_snapshot: LM Studio MLX 8-bit model id lmstudio-community/gemma-4-31B-it-MLX-8bit
runtime: LM Studio local OpenAI-compatible HTTP server; MLX runtime
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 32768
max_tokens: 1024
seed: 303
prompt_source: condition packet (substrate_workflow) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 61d771e2bff7fd2e18be1d2999d0f601760656e3e69b4622989ca7bffd3aff8e
source_packet: a substrate preamble plus three reviewed source cards, then the frozen Advisor prompt - see run-packet.md
source_packet_sha256: 8c1fbdb9b2af9238d4533dece4ffc185fda2e1f7ecb6008913243d23d9a67c63
condition_packet_sha256: 8c1fbdb9b2af9238d4533dece4ffc185fda2e1f7ecb6008913243d23d9a67c63
output_file: model-outputs/substrate_workflow-03.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - substrate_workflow (run 03)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v9-v1`, condition `substrate_workflow`, run 3 of 8. Real local-model run: `gemma-4-31b-it-mlx` via lmstudio, seed 303, on the frozen condition packet.

## Output

I recommend that you commit to the **Claim File Review**.

### Rationale
The current evidence for DraftPath’s success is heavily contaminated by "performance-aware attribution" (BK-0048). The executive team’s praise for the product team's "discipline" and "alignment" follows a strong quarter, but that strength is likely driven by temporary bundle pricing and sales pitches rather than product value.

The core uncertainty is whether DraftPath solves a real problem for the user or if it is merely "activity" that looks like progress (BK-0007). Usage rose 39%, but the data reveals this is driven by managers (not adjusters) and initial novelty. The most critical failure point is the "explainability" gap in regulated health-liability, where users abandon the tool because they cannot justify its output to reviewers.

The **Claim File Review** is the only proposal that provides a "load-bearing diagnosis" (BK-0001) of the actual challenge. By inspecting whether suggestions were accepted, overridden, or impossible to explain, you move past "broad activity metrics" and determine if the product is actually functioning as a workflow solution or merely a decorative feature.

*   **Why not the Usage Quality Sprint?** This focuses on "enablement" and "return rates," which are activity metrics that can fail to disconfirm the favored story (BK-0007).
*   **Why not the Commercial Cleanroom?** While it tests pricing sensitivity, it does not tell you *why* the product is failing in specific segments or how to fix the core value proposition.
*   **Why not Scale Broadly?** Scaling based on contaminated data risks baking in a flawed strategy.

### The Strongest Reason Against This Recommendation
The Claim File Review is qualitative and slow. It provides a deep understanding of *why* the product fails, but it does not provide the immediate, quantitative "proof" of revenue protection that a board often demands during budget locks. It risks being dismissed as "endless analysis" (BK-0001) rather than a decisive strategic step.

### Evidence That Would Change My Mind
I would change this recommendation if the **Commercial Cleanroom** results (if run) showed that expansion bookings remained stable even without bundle pricing and roadmap pitches. If the financial lift were decoupled from sales incentives, it would suggest the value proposition is strong enough to survive the current "explainability" issues, making broad scaling a lower-risk bet.
